Decreased expression of CYP27B1 correlates with the increased aggressiveness of ovarian carcinomas

Brożyna,Anna A.; Jóźwicki,Wojciech; Jochymski,Cezary; Slominski,Andrzej T.

doi:10.3892/or.2014.3666

Decreased expression of CYP27B1 correlates with the increased aggressiveness of ovarian carcinomas

Authors:
- Anna A. Brożyna
- Wojciech Jóźwicki
- Cezary Jochymski
- Andrzej T. Slominski
View Affiliations

Affiliations: Department of Tumor Pathology and Pathomorphology, Oncology Centre, Prof. Franciszek Łukaszczyk Memorial Hospital, The Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, 85‑796 Bydgoszcz, Poland, Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA
Published online on: December 11, 2014 https://doi.org/10.3892/or.2014.3666
Pages: 599-606

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CYP27B1 hydroxylates 25-hydroxyvitamin D3 in position C1α into biologically active 1,25-dihydroxyvitamin D3, calcitriol. CYP27B1 is expressed in normal tissues and tumors. Since calcitriol indicates anticancer activities and CYP27B1 expression can be deregulated during malignant progression, we analyzed its expression in ovarian cancers in relation to pathomorphological features of tumors and overall survival (OS). Expression of CYP27B1 was evaluated in 61 ovarian tumors, 18 metastases and 10 normal ovaries. Normal ovarian epithelium showed the highest levels CYP27B1 with a significant decrease in its expression in ovarian cancers. Both poorly differentiated primary tumors and metastases showed the lowest level of CYP27B1 expression, while non-metastasizing tumors showed a higher CYP27B1 level than tumors that developed metastases. The expression of CYP27B1 was positively correlated with a lower proliferation rate, lower dynamism of tumor growth and tumor infiltrating lymphocyte response. Furthermore, CYP27B1 expression was negatively correlated with tumor cell modeling of their microenvironment. CYP27B1 expression was also associated with longer OS time. In summary, our results suggest that local expression of CYP27B1 in ovarian tumor cells can modify their behavior and promote a less aggressive phenotype by affecting local concentrations of active of vitamin D levels within the tumor microenvironment.

View Figures

View References

1	Bikle D: Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 94:26–34. 2009. View Article : Google Scholar :
2	Holick MF: Vitamin D: Its role in cancer prevention and treatment. Prog Biophys Mol Biol. 92:49–59. 2006. View Article : Google Scholar : PubMed/NCBI
3	Holick MF: Vitamin D deficiency. N Engl J Med. 357:266–281. 2007. View Article : Google Scholar : PubMed/NCBI
4	Plum LA and DeLuca HF: Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov. 9:941–955. 2010. View Article : Google Scholar : PubMed/NCBI
5	Hewison M: Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin North Am. 39:365–379. 2010. View Article : Google Scholar : PubMed/NCBI
6	van Etten E, Stoffels K, Gysemans C, Mathieu C and Overbergh L: Regulation of vitamin D homeostasis: implications for the immune system. Nutr Rev. 66(Suppl 2): S125–S134. 2008. View Article : Google Scholar : PubMed/NCBI
7	Holick MF: Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 79:362–371. 2004.PubMed/NCBI
8	Holick MF: Vitamin D and sunlight: strategies for cancer prevention and other health benefits. Clin J Am Soc Nephrol. 3:1548–1554. 2008. View Article : Google Scholar : PubMed/NCBI
9	Spina CS, Tangpricha V, Uskokovic M, Adorinic L, Maehr H and Holick MF: Vitamin D and cancer. Anticancer Res. 26:2515–2524. 2006.PubMed/NCBI
10	Walsh JE, Clark AM, Day TA, Gillespie MB and Young MR: Use of α,25-dihydroxyvitamin D₃ treatment to stimulate immune infiltration into head and neck squamous cell carcinoma. Hum Immunol. 71:659–665. 2010. View Article : Google Scholar : PubMed/NCBI
11	Welsh J: Cellular and molecular effects of vitamin D on carcinogenesis. Arch Biochem Biophys. 523:107–114. 2012. View Article : Google Scholar :
12	Mehta RG, Hussain EA, Mehta RR and Das Gupta TK: Chemoprevention of mammary carcinogenesis by 1α-hydroxyvitamin D₅, a synthetic analog of vitamin D. Mutat Res. 523–524:253–264. 2003. View Article : Google Scholar
13	Peng X, Hawthorne M, Vaishnav A, St-Arnaud R and Mehta RG: 25-Hydroxyvitamin D₃ is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res Treat. 113:31–41. 2009. View Article : Google Scholar :
14	Pommergaard HC, Burcharth J, Rosenberg J and Raskov H: Chemoprevention with acetylsalicylic acid, vitamin D and calcium reduces risk of carcinogen-induced lung tumors. Anticancer Res. 33:4767–4770. 2013.PubMed/NCBI
15	Fedirko V, Bostick RM, Long Q, et al: Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 19:280–291. 2010. View Article : Google Scholar : PubMed/NCBI
16	Slominski AT, Kim TK, Li W, Yi AK, Postlethwaite A and Tuckey RC: The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions. J Steroid Biochem Mol Biol. 144PA:28–39. 2014. View Article : Google Scholar
17	Slominski AT, Janjetovic Z, Kim TK, et al: Novel vitamin d hydroxyderivatives inhibit melanoma growth and show differential effects on normal melanocytes. Anticancer Res. 32:3733–3742. 2012.PubMed/NCBI
18	Bikle DD: Vitamin D: an ancient hormone. Exp Dermatol. 20:7–13. 2011. View Article : Google Scholar : PubMed/NCBI
19	Bikle DD: Vitamin D and the skin: physiology and pathophysiology. Rev Endocr Metab Disord. 13:3–19. 2012. View Article : Google Scholar
20	Thorne J and Campbell MJ: The vitamin D receptor in cancer. Proc Nutr Soc. 67:115–127. 2008. View Article : Google Scholar : PubMed/NCBI
21	Brożyna AA, Jozwicki W, Janjetovic Z and Slominski AT: Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum Pathol. 42:618–631. 2011. View Article : Google Scholar
22	Anderson MG, Nakane M, Ruan X, Kroeger PE and Wu-Wong JR: Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol. 57:234–240. 2006. View Article : Google Scholar
23	Brożyna AA, Jóźwicki W and Slominski AT: Decreased VDR expression in cutaneous melanomas as marker of tumor progression: new data and analyses. Anticancer Res. 34:2735–2744. 2014.
24	Matusiak D, Murillo G, Carroll RE, Mehta RG and Benya RV: Expression of vitamin D receptor and 25-hydroxyvitamin D3-1α-hydroxylase in normal and malignant human colon. Cancer Epidemiol Biomarkers Prev. 14:2370–2376. 2005. View Article : Google Scholar : PubMed/NCBI
25	Menezes RJ, Cheney RT, Husain A, et al: Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomarkers Prev. 17:1104–1110. 2008. View Article : Google Scholar : PubMed/NCBI
26	Fu Y, Li J and Zhang Y: Polymorphisms in the vitamin D receptor gene and the lung cancer risk. Tumour Biol. 35:1323–1330. 2014. View Article : Google Scholar
27	Randerson-Moor JA, Taylor JC, Elliott F, et al: Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer. 45:3271–3281. 2009. View Article : Google Scholar : PubMed/NCBI
28	Shan JL, Dai N, Yang XQ, et al: FokI polymorphism in vitamin D receptor gene and risk of breast cancer among Caucasian women. Tumour Biol. 35:3503–3508. 2014. View Article : Google Scholar
29	Li S, Xu H, Li SC, Qi XQ and Sun WJ: Vitamin D receptor rs2228570 polymorphism and susceptibly to ovarian cancer: a meta-analysis. Tumour Biol. 35:1319–1322. 2014. View Article : Google Scholar
30	Liu Y, Li C, Chen P, et al: Polymorphisms in the vitamin D receptor (VDR) and the risk of ovarian cancer: a meta-analysis. PLoS One. 8:e667162013. View Article : Google Scholar : PubMed/NCBI
31	Xu H, Li S, Qiu JQ, Gao XL, Zhang P and Yang YX: The VDR gene Fok I polymorphism and ovarian cancer risk. Tumour Biol. 34:3309–3316. 2013. View Article : Google Scholar : PubMed/NCBI
32	Zehnder D, Bland R, Walker EA, et al: Expression of 25-hydroxyvitamin D₃-1α-hydroxylase in the human kidney. J Am Soc Nephrol. 10:2465–2473. 1999.PubMed/NCBI
33	Slominski AT, Kim TK, Shehabi HZ, et al: In vivo evidence for a novel pathway of vitamin D₃ metabolism initiated by P450scc and modified by CYP27B1. FASEB J. 26:3901–3915. 2012. View Article : Google Scholar : PubMed/NCBI
34	Slominski AT, Kim TK, Shehabi HZ, et al: In vivo production of novel vitamin D2 hydroxy-derivatives by human placentas, epidermal keratinocytes, Caco-2 colon cells and the adrenal gland. Mol Cell Endocrinol. 383:181–192. 2014. View Article : Google Scholar : PubMed/NCBI
35	Radermacher J, Diesel B, Seifert M, et al: Expression analysis of CYP27B1 in tumor biopsies and cell cultures. Anticancer Res. 26:2683–2686. 2006.PubMed/NCBI
36	Tangpricha V, Flanagan JN, Whitlatch LW, et al: 25-hydroxyvitamin D-1α-hydroxylase in normal and malignant colon tissue. Lancet. 357:1673–1674. 2001. View Article : Google Scholar : PubMed/NCBI
37	Lopes N, Sousa B, Martins D, et al: Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions Vitamin D pathways unbalanced in breast lesions. BMC Cancer. 10:4832010. View Article : Google Scholar :
38	Evans KN, Taylor H, Zehnder D, et al: Increased expression of 25-hydroxyvitamin D-1α-hydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy. Am J Pathol. 165:807–813. 2004. View Article : Google Scholar : PubMed/NCBI
39	Takeyama K and Kato S: The vitamin D3 1α-hydroxylase gene and its regulation by active vitamin D3. Biosci Biotechnol Biochem. 75:208–213. 2011. View Article : Google Scholar
40	Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK and Gorham ED: Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet. 2:1176–1178. 1989. View Article : Google Scholar : PubMed/NCBI
41	Hanchette CL and Schwartz GG: Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer. 70:2861–2869. 1992. View Article : Google Scholar : PubMed/NCBI
42	Hiatt RA, Krieger N, Lobaugh B, Drezner MK, Vogelman JH and Orentreich N: Prediagnostic serum vitamin D and breast cancer. J Natl Cancer Inst. 90:461–463. 1998. View Article : Google Scholar : PubMed/NCBI
43	International Agency for Research on Cancer. Vitamin D and Cancer. 5. IARC; Lyon: 2008
44	Petrioli R, Pascucci A, Francini E, et al: Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU Int. 100:775–779. 2007. View Article : Google Scholar : PubMed/NCBI
45	Walentowicz-Sadlecka M, Grabiec M, Sadlecki P, et al: 25(OH) D3 in patients with ovarian cancer and its correlation with survival. Clin Biochem. 45:1568–1572. 2012. View Article : Google Scholar : PubMed/NCBI
46	Redaniel MT, Gardner MP, Martin RM and Jeffreys M: The association of vitamin D supplementation with the risk of cancer in postmenopausal women. Cancer Causes Control. 25:267–271. 2014. View Article : Google Scholar
47	Tavassoli FA and Devilee P: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press; Lyon: 2003
48	Brożyna AA, Jóźwicki W, Janjetovic Z and Slominski AT: Expression of the vitamin D-activating enzyme 1α-hydroxylase (CYP27B1) decreases during melanoma progression. Hum Pathol. 44:374–387. 2013. View Article : Google Scholar
49	Janjetovic Z, Brozyna AA, Tuckey RC, et al: High basal NF-κB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives. Br J Cancer. 105:1874–1884. 2011. View Article : Google Scholar : PubMed/NCBI
50	Jozwicki W, Windorbska W, Brozyna AA, et al: The analysis of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) immunoreactivity within the microenvironment of the ovarian cancer lesion relative to the applied therapeutic strategy. Cell Tissue Res. 345:405–414. 2011. View Article : Google Scholar : PubMed/NCBI
51	Hwang WT, Adams SF, Tahirovic E, Hagemann IS and Coukos G: Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 124:192–198. 2012. View Article : Google Scholar :
52	Webb JR, Milne K, Watson P, Deleeuw RJ and Nelson BH: Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res. 20:434–444. 2014. View Article : Google Scholar
53	Holick MF: Vitamin D: evolutionary, physiological and health perspectives. Curr Drug Targets. 12:4–18. 2011. View Article : Google Scholar
54	Bises G, Kallay E, Weiland T, et al: 25-hydroxyvitamin D₃-1α-hydroxylase expression in normal and malignant human colon. J Histochem Cytochem. 52:985–989. 2004. View Article : Google Scholar : PubMed/NCBI
55	Clinckspoor I, Hauben E, Verlinden L, et al: Altered expression of key players in vitamin D metabolism and signaling in malignant and benign thyroid tumors. J Histochem Cytochem. 60:502–511. 2012.PubMed/NCBI
56	Hsu JY, Feldman D, McNeal JE and Peehl DM: Reduced 1α-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D₃-induced growth inhibition. Cancer Res. 61:2852–2856. 2001.PubMed/NCBI
57	Friedrich M, Diesing D, Cordes T, et al: Analysis of 25-hydroxyvitamin D₃-1α-hydroxylase in normal and malignant breast tissue. Anticancer Res. 26:2615–2620. 2006.PubMed/NCBI
58	Agic A, Xu H, Altgassen C, et al: Relative expression of 1,25-dihydroxyvitamin D3 receptor, vitamin D 1α-hydroxylase, vitamin D 24-hydroxylase, and vitamin D 25-hydroxylase in endometriosis and gynecologic cancers. Reprod Sci. 14:486–497. 2007. View Article : Google Scholar : PubMed/NCBI
59	Fischer D, Thome M, Becker S, et al: 25-Hydroxyvitamin D₃ 1α-hydroxylase splice variants in benign and malignant ovarian cell lines and tissue. Anticancer Res. 29:3627–3633. 2009.PubMed/NCBI
60	Reichrath J, Rafi L, Rech M, et al: Analysis of the vitamin D system in cutaneous squamous cell carcinomas. J Cutan Pathol. 31:224–231. 2004. View Article : Google Scholar : PubMed/NCBI
61	Urbschat A, Paulus P, von Quernheim QF, et al: Vitamin D hydroxylases CYP2R1, CYP27B1 and CYP24A1 in renal cell carcinoma. Eur J Clin Invest. 43:1282–1290. 2012. View Article : Google Scholar
62	Flanagan JN, Wang L, Tangpricha V, Reichrath J, Chen TC and Holick MF: Regulation of the 25-hydroxyvitamin D-1α-hydroxylase gene and its splice variant. Recent Results Cancer Res. 164:157–167. 2003. View Article : Google Scholar
63	Wu S, Ren S, Nguyen L, Adams JS and Hewison M: Splice variants of the CYP27b1 gene and the regulation of 1,25-dihydroxyvitamin D₃ production. Endocrinology. 148:3410–3418. 2007. View Article : Google Scholar : PubMed/NCBI
64	Fischer D, Seifert M, Becker S, et al: 25-Hydroxyvitamin D₃ 1α-hydroxylase splice variants in breast cell lines MCF-7 and MCF-10. Cancer Genomics Proteomics. 4:295–300. 2007.PubMed/NCBI